1-20 of 23
Mark Raffeld
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial

Melissa L. Abel, Nobuyuki Takahashi, Cody Peer, Christophe E. Redon, Samantha Nichols, Rasa Vilimas, Min-Jung Lee, Sunmin Lee, Meenakshi Shelat, Robbie Kattappuram, Linda Sciuto, Danielle Pinkiert, Chante Graham, Donna Butcher, Baktiar Karim, Ajit Kumar Sharma, Justin Malin, Rajesh Kumar, Christopher W. Schultz, Shubhank Goyal, Jaydira del Rivero, Manan Krishnamurthy, Deep Upadhyay, Brett Schroeder, Tristan Sissung, Manoj Tyagi, Jung Kim, Yves Pommier, Mirit Aladjem, Mark Raffeld, William Douglas Figg, Jane Trepel, Liqiang Xi, Parth Desai, Anish Thomas
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3603–3611.
https://doi.org/10.1158/1078-0432.CCR-23-0536
Published: 15 September 2023
View articletitled, Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Open the PDF for Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens

Parisa Malekzadeh, Rami Yossef, Gal Cafri, Biman C. Paria, Frank J. Lowery, Mohammad Jafferji, Meghan L. Good, Abraham Sachs, Amy R. Copeland, Sanghyun P. Kim, Scott Kivitz, Maria R. Parkhurst, Paul F. Robbins, Satyajit Ray, Liqiang Xi, Mark Raffeld, Zhiya Yu, Nicholas P. Restifo, Robert P.T. Somerville, Steven A. Rosenberg, Drew C. Deniger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1267–1276.
https://doi.org/10.1158/1078-0432.CCR-19-1874
Published: 13 March 2020
View articletitled, Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Open the PDF for Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma

Kamal Sharma, John E. Janik, Deirdre O'Mahony, Donn Stewart, Stefania Pittaluga, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Mark Raffeld, Thomas A. Fleisher, Cathryn C. Lee, Seth M. Steinberg, Thomas A. Waldmann, John C. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 35–42.
https://doi.org/10.1158/1078-0432.CCR-16-1022
Published: 02 January 2017
View articletitled, Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
Open the PDF for Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma

Liqiang Xi, Trinh Hoc-Tran Pham, Eden C. Payabyab, Richard M. Sherry, Steven A. Rosenberg, Mark Raffeld
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5480–5486.
https://doi.org/10.1158/1078-0432.CCR-16-0613
Published: 14 November 2016
View articletitled, Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
Open the PDF for Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Identification of an Immunogenic Subset of Metastatic Uveal Melanoma

Luke D. Rothermel, Arvind C. Sabesan, Daniel J. Stephens, Smita S. Chandran, Biman C. Paria, Abhishek K. Srivastava, Robert Somerville, John R. Wunderlich, Chyi-Chia R. Lee, Liqiang Xi, Trinh H. Pham, Mark Raffeld, Parthav Jailwala, Manjula Kasoji, Udai S. Kammula
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2237–2249.
https://doi.org/10.1158/1078-0432.CCR-15-2294
Published: 01 May 2016
View articletitled, Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
Open the PDF for Identification of an Immunogenic Subset of Metastatic Uveal Melanoma in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z. Badros, Peter M. Voorhees, Rachid Baz, Neha Korde, Hui-Yi Lin, Jin-Qiu Chen, Michelle Herrmann, Liqiang Xi, Mark Raffeld, Xiuhua Zhao, Wen Wan, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Heidi Sankala, Kevin T. Hogan, Austin Doyle, Christina M. Annunziata, Martha Wellons, John D. Roberts, Daniel Sullivan, Ola Landgren, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1067–1075.
https://doi.org/10.1158/1078-0432.CCR-15-1076
Published: 29 February 2016
View articletitled, A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Open the PDF for A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

Lindsey M. Draper, Mei Li M. Kwong, Alena Gros, Sanja Stevanović, Eric Tran, Sid Kerkar, Mark Raffeld, Steven A. Rosenberg, Christian S. Hinrichs
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4431–4439.
https://doi.org/10.1158/1078-0432.CCR-14-3341
Published: 30 September 2015
View articletitled, Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Open the PDF for Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6 in another window
Includes: Supplementary data
Journal Articles

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, Steven A. Rosenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1019–1027.
https://doi.org/10.1158/1078-0432.CCR-14-2708
Published: 01 March 2015
View articletitled, A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Open the PDF for A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response in another window
Includes: Supplementary data
Journal Articles

Minimal residual disease in hairy cell leukemia patients treated by BL22

Eugeny Arons, Joel Sunshine, Tara Suntum, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A51.
Published: 15 August 2014
View articletitled, Minimal residual disease in hairy cell leukemia patients treated by BL22
Journal Articles

Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia

Robert J. Kreitman, Wyndham Wilson, Katherine R. Calvo, Evgeny Arons, Laura Roth, Jeffrey Sapolsky, Hong Zhou, Mark Raffeld, Maryalice Stetler-Stevenson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6873–6881.
https://doi.org/10.1158/1078-0432.CCR-13-1752
Published: 16 December 2013
View articletitled, Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia
Open the PDF for Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia in another window
Journal Articles

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Robert O. Carpenter, Moses O. Evbuomwan, Stefania Pittaluga, Jeremy J. Rose, Mark Raffeld, Shicheng Yang, Ronald E. Gress, Frances T. Hakim, James N. Kochenderfer
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2048–2060.
https://doi.org/10.1158/1078-0432.CCR-12-2422
Published: 15 April 2013
View articletitled, B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Open the PDF for B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases

Anna Tamburrino, Alfredo A. Molinolo, Paolo Salerno, Rebecca D. Chernock, Mark Raffeld, Liqiang Xi, J. Silvio Gutkind, Jeffrey F. Moley, Samuel A. Wells, Jr., Massimo Santoro
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (13): 3532–3540.
https://doi.org/10.1158/1078-0432.CCR-11-2700
Published: 01 July 2012
View articletitled, Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases
Open the PDF for Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases in another window
Includes: Supplementary data
Journal Articles

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Shivaani Kummar, Mark Raffeld, Lamin Juwara, Yvonne Horneffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Ismail Baris Turkbey, Peter Choyke, Anthony J. Murgo, James H. Doroshow, Giovanni Melillo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5123–5131.
https://doi.org/10.1158/1078-0432.CCR-11-0682
Published: 31 July 2011
View articletitled, Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Open the PDF for Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1190–1199.
https://doi.org/10.1158/1078-0432.CCR-10-2331
Published: 01 March 2011
View articletitled, Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Open the PDF for Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib in another window
Includes: Supplementary data
Journal Articles

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Deirdre O'Mahony, John C. Morris, Maryalice Stetler-Stevenson, Helen Matthews, Margaret R. Brown, Thomas Fleisher, Stefania Pittaluga, Mark Raffeld, Paul S. Albert, Dirk Reitsma, Karen Kaucic, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2514–2522.
https://doi.org/10.1158/1078-0432.CCR-08-1254
Published: 01 April 2009
View articletitled, EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Open the PDF for EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies in another window
Includes: Supplementary data
Journal Articles

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

Yoko Tabe, Denise Sebasigari, Linhua Jin, Martina Rudelius, Theresa Davies-Hill, Kazunori Miyake, Takashi Miida, Stefania Pittaluga, Mark Raffeld
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (3): 933–942.
https://doi.org/10.1158/1078-0432.CCR-08-0399
Published: 02 February 2009
View articletitled, MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
Open the PDF for MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma in another window
Journal Articles

Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction

Evgeny Arons, Inger Margulies, Lynn Sorbara, Mark Raffeld, Maryalice Stetler-Stevenson, Ira Pastan, Robert J. Kreitman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2804–2811.
https://doi.org/10.1158/1078-0432.CCR-05-2315
Published: 04 May 2006
View articletitled, Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction
Open the PDF for Minimal Residual Disease in Hairy Cell Leukemia Patients Assessed by Clone-Specific Polymerase Chain Reaction in another window
Journal Articles

Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma

Christian Gulmann, Virginia Espina, Emanuel Petricoin, III, Dan L. Longo, Mariarita Santi, Turid Knutsen, Mark Raffeld, Elaine S. Jaffe, Lance A. Liotta, Andrew L. Feldman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5847–5855.
https://doi.org/10.1158/1078-0432.CCR-05-0637
Published: 22 August 2005
View articletitled, Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma
Open the PDF for Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma in another window
Journal Articles

Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases

Masayuki Furukawa, Mark Raffeld, Carmen Mateo, Akio Sakamoto, Terry W. Moody, Tetsuhide Ito, David J. Venzon, Jose Serrano, Robert T. Jensen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3233–3242.
https://doi.org/10.1158/1078-0432.CCR-04-1915
Published: 02 May 2005
View articletitled, Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases
Open the PDF for Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases in another window
Journal Articles

Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Meera Srivastava, Lukas Bubendorf, Mark Raffeld, Christoph Bucher, Jochen Torhorst, Guido Sauter, Cara Olsen, Olli P. Kallioniemi, Ofer Eidelman, Harvey B. Pollard
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2344–2350.
https://doi.org/10.1158/1078-0432.CCR-03-0278
Published: 08 April 2004
View articletitled, Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients
Open the PDF for Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients in another window